Lumida
/SOLV
⌘K
Solventum Corp

Solventum Corp

SOLV
$87.45USD-0.23%-0.20 today

MARKET CAP

14.9B

P/E (TTM)

10.7x

FWD P/E

DAY RANGE

$87 – $89

52W RANGE

$62
$94

AI Summary

Stalk
TrimMedium

SOLV's break below key horizontal support at $87.45 on elevated volume signals a medium-term bearish continuation, but short-term price is extended below the 9- and 20-day EMAs without a pullback into the former support zone. Execution is deferred—monitor for a rebound toward the broken support area and dynamic EMA resistance to sell with better conviction. The longer-term uptrend remains intact above the 200-day SMA, anchoring structural context.

  • Q2 revenue $2.2B (+9.5% organic YoY) with EPS $2.55 beating estimates
  • HIS business separation to sharpen focus on MedSurg and dental
  • Negative growth revisions signal slowing top-line momentum ahead
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Solventum Corporation (NYSE: SOLV) operates within the medical technology sector, focusing on a diversified product portfolio that includes MedSurg and dental solutions, alongside specialized health information systems (HIS). The company is currently undergoing a significant transformation to optimize its operations and unlock shareholder value through strategic asset management, notably the impending separation of its HIS segment. Solventum is capitalizing on the growing demand for medical technologies, seeking to enhance its market position amid a landscape that emphasizes innovation and improved healthcare outcomes.

Bull says

  • Q2 revenue $2.2B (+9.5% organic YoY) with EPS $2.55 beating estimates
  • HIS business separation to sharpen focus on MedSurg and dental
  • $288M share repurchases (~4M shares) reflect disciplined capital allocation
  • FY26 organic sales guidance 2.5–3% with 20 new launches by 2028
  • P/E 10.8 attractive; high earnings yield and solid book-to-price ratio

Bear says

  • Negative growth revisions signal slowing top-line momentum ahead
  • Q2 margin 28.4% includes one-time tariff refund; core margin ~21.7%
  • HIS spin-off execution risk may disrupt near-term operations
  • Volatile procedure volumes could dent revenues amid market swings
  • Low dividend yield deters income investors during reinvestment phase
  • Quality and size concerns may hamper traction in prolonged downturn

Investment themes with SOLV

Health Care Equipment & Supplies +0.40%

Clinical instruments and devices powering patient care

ABT · ISRG · SYK
SPY +0.09%

NVDA · AAPL · GOOGL
Others +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY

Earnings Call · Q3 2024 · Mgmt. Guidance

Updated 12-24-2025bullish

Transcript signals

Bull points

  • raise our full-year organic growth rate to the upper half of our prior guidance of flat to 1%
  • we're increasing our adjusted EPS and free cash flow guidance ranges as well
  • we officially launched the back peel-in-place dressing that we've been talking about, which gives us three advantages: simplifying the procedure, reducing procedure time, and reducing the number of dressing changes per week
Read full transcript analysis ›